ReviewBioMed research international2014
Preclinical and clinical effects of mistletoe against breast cancer.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.CA: a cancer journal for clinicians · 2017Guideline
- Medicinal Plants and Phytochemicals in Cardioprotection-Mechanistic Pathways and Translational Roadmap.Life (Basel, Switzerland) · 2026Review
- Phytonutrient Profiles of Mistletoe and Their Values and Potential Applications in Ethnopharmacology and Nutraceuticals: A Review.Molecules (Basel, Switzerland) · 2025Review
- Article
- Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models.International journal of molecular sciences · 2025Article
- Comparative analysis of IscM and IscQu in feline oral squamous cell carcinoma treatment: cytotoxic and apoptotic insights.Frontiers in veterinary science · 2025Article
- Traditional Uses, Phytochemical Constituents and Ethnopharmacological Properties of Mistletoe from Phoradendron and Viscum Species.Combinatorial chemistry & high throughput screening · 2024Review
- Skin Cancer: An Insight on its Association with Aging, Pathogenesis and Treatment Strategies.Current drug research reviews · 2024Review
- A Scoping Review of GenusPlants (Basel, Switzerland) · 2023Article
- A Comprehensive Review on Pharmacological Activities of Pachypodol: A Bioactive Compound of an Aromatic Medicinal Plant Pogostemon Cablin Benth.Molecules (Basel, Switzerland) · 2023Review
- Antitumor Effect of Iscador on Breast Cancer Cell Lines with Different Metastatic Potential.International journal of molecular sciences · 2023Article
- In-Vitro Growth Kinetics of Mesenchymal Stem Cells in Cytotoxicity Tests Using Low-Diluted Viscum Album.Homeopathy : the journal of the Faculty of Homeopathy · 2023Article
- Inhibition of osteosarcoma by European Mistletoe derived val-miR218.Extracellular vesicles and circulating nucleic acids · 2023Article
- Phytochemical Profile and Antioxidant Capacity ofPlants (Basel, Switzerland) · 2022Article
- Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity.Cancers · 2022Article
- How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?Pharmaceuticals (Basel, Switzerland) · 2022Review
- RomanianPlants (Basel, Switzerland) · 2022Article
- Glycosylation-Dependent Induction of Programmed Cell Death in Murine Adenocarcinoma Cells.Frontiers in immunology · 2022Article
- Plants in Anticancer Drug Discovery: From Molecular Mechanism to Chemoprevention.BioMed research international · 2022Review
- Impact of Harvest Conditions and Host Tree Species on Chemical Composition and Antioxidant Activity of Extracts fromMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is among the most frequent types of cancer in women worldwide. Current conventional treatment options are accompanied by side effects. Mistletoe is amongst the important herbal medicines traditionally used as complementary remedies. An increasing number of studies have reported anticancer activity of mistletoe extracts on breast cancer cells and animal models. Some recent evidence suggests that cytotoxic activity of mistletoe may be mediated through different mechanisms. These findings provide a good base for clinical trials. Various studies on mistletoe therapy for breast cancer patients revealed similar findings concerning possible benefits on survival time, health-related quality of life (HRQoL), remission rate, and alleviating adverse reactions to conventional therapy. This review provides an overview of the recent findings on preclinical experiments and clinical trials of mistletoe for its cytotoxic and antitumor activity and its effect on HRQoL in breast cancer patients. Moreover, studies investigating molecular and cellular mechanisms underlying antitumor activity of mistletoe are discussed in this paper. The analyzed trials provided evidence that there might be a combination of pharmacological and motivational aspects mediated by the mistletoe extract application which may contribute to the clinical benefit and positive outcome such as improved HRQoL and self-regulation in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.